<?xml version="1.0" encoding="UTF-8"?>
<ref id="BST-47-1757C75">
 <label>75</label>
 <mixed-citation publication-type="journal">
  <person-group person-group-type="author">
   <name name-style="western">
    <surname>Greer</surname>
    <given-names>Y.</given-names>
   </name>, 
   <name name-style="western">
    <surname>Porat-Shliom</surname>
    <given-names>N.</given-names>
   </name>, 
   <name name-style="western">
    <surname>Nagashima</surname>
    <given-names>K.</given-names>
   </name>, 
   <name name-style="western">
    <surname>Stuelten</surname>
    <given-names>C.</given-names>
   </name>, 
   <name name-style="western">
    <surname>Crooks</surname>
    <given-names>D.</given-names>
   </name>, 
   <name name-style="western">
    <surname>Koparde</surname>
    <given-names>V.</given-names>
   </name>
   <etal>et al.</etal>
  </person-group> (
  <year>2018</year>) 
  <article-title>ONC201 kills breast cancer cells in vitro by targeting mitochondria</article-title>. 
  <source>Oncotarget</source>
  <volume>9</volume>
  <pub-id pub-id-type="doi">10.18632/oncotarget.24862</pub-id>
 </mixed-citation>
</ref>
